CK
Chinni Krishnareddy Gangireddy
Vice President Of Manufacturing at Hetero
View Chinni's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Vice President Of Manufacturing
Nov 2022 - Present · 2 years and 1 months
Therapiva Pvt. Ltd
Operations Head
Jul 2021 - Oct 2022 · 1 years and 3 months
Head Of Site Operations
Sep 2017 - May 2021 · 3 years and 8 months
Company Details
10000+ Employees
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc. Hetero has a strong global presence in over 145+ countries and focusses on making affordable medicines accessible to patients worldwide.
Year Founded
1993
Social Media
LinkedinFacebookTwitterInstagram
Industry
Pharmaceutical Manufacturing, Pharmaceutical Ointments & Creams, Pharmaceuticals, Indian Exporters
HQ Location
7-2-A2, Hetero Corporate Industrial Estates. Hyderabad - 500 018. Telangana, India Sanath Nagar HYDERABAD, Telangana 500 018, IN
Keywords
Active pharmaceutical ingredientCustom Pharma Servicesbiosimilarsand Generic medicine
Discover More About Cleveland Clinic

Find verified contacts of Chinni Krishnareddy Gangireddy in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.